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Hepatic lipase (HL) and scavenger receptor type B
class I (SR-BI) have both been implicated in high density
lipoprotein (HDL)-cholesteryl ester uptake in cholester-
ol-utilizing tissues. Inactivation of HL by gene-directed
targeting in mice results in up-regulation of SR-BI ex-
pression in adrenal gland (Wang, N., Weng, W., Breslow,
J. L., and Tall, A. R. (1996) J. Biol. Chem. 271, 21001–
21004). The net effect on HDL-cholesteryl ester uptake is
not known.
We determined the impact of acute in vivo inhibition
of rat adrenal HL activity by antibodies on SR-BI ex-
pression and on human and rat HDL-[3H]cholesteryl
ether (CEth) uptake in the adrenal gland. Rat HDL was
isolated from rats in which HL activity had been inhib-
ited for 1 h. The rats were studied under basal condi-
tions (not ACTH-treated) and after previous treatment
with ACTH for 6 days (ACTH-treated). Intravenous in-
jection of anti-HL resulted in 70% lowering of adrenal
HL activity in both conditions which were maintained
for at least 8 h. In not ACTH-treated rats, inhibition of
adrenal HL increased adrenal SR-BI mRNA (5.2-fold)
and mass (1.6-fold) within 4 h. HL inhibition resulted in
41% and 14% more adrenal accumulation of human HDL-
[3H]CEth during 4 and 24 h, respectively. The adrenal
uptake of rat HDL-[3H]CEth increased by 68%, 4 h after
the antibody injection. ACTH treatment increased total
adrenal HL activity from 3.7 6 0.5 milliunits to 34.0 6
17.2 milliunits, as well as adrenal SR-BI mRNA from
2.9 6 0.7 arbitrary units (A.U.) to 86.8 6 41.1 A.U. and
SR-BI mass from 7.7 6 1.8 A.U. to 63.16 6 46.7 A.U. The
human HDL-[3H]CEth uptake by adrenals was also sig-
nificantly increased from 0.58 6 0.11% of injected dose to
7.24 6 1.58% of injected dose. Inhibition of adrenal HL
activity did not result in further induction of SR-BI ex-
pression and did not affect human HDL-[3H]CEth
uptake.
These findings indicate that SR-BI expression may be
influenced by changes in HL activity. HL activity is not
needed for the SR-BI-mediated HDL-cholesteryl ester
uptake by rat adrenal glands.
In the rat, hepatic lipase (HL1; E.C. 3.1.1.34) is extracellu-
larly localized at the parenchymal cell microvilli of the liver
(1–3). A related enzyme, also indicated as liver (L)-type lipase,
is present in the zona fasciculata of the adrenal gland and in
the corpora lutea of the ovary (2, 4–6). We proposed a role of
HL in the uptake of HDL-unesterified cholesterol and cho-
lesteryl esters in the lipase-containing tissues (7, 8). In vitro
studies, with either isolated cell systems or perfused rat liver,
showed that HL activity may stimulate the uptake of HDL-
cholesteryl esters as well as unesterified cholesterol (9–11).
However, in vivo only indirect support for a role of HL in
HDL-cholesterol and cholesteryl ester uptake has been ob-
tained. Jansen et al. (12) showed that plasma HDL-cholesterol
increased by in vivo inhibition of HL. At the same time de novo
cholesterol synthesis in liver (13) and in superovulated rat
ovaries (14) is induced. These findings are compatible with the
involvement of HL in the uptake of extracellular cholesterol.
HDL-cholesteryl ester uptake has been studied in a wide range
of tissues under different metabolic conditions and may be
taken up via several mechanisms. Besides the classical endo-
cytotic pathway (see Ref. 15 as review) a selective uptake
mechanism, in which HDL-cholesteryl esters are taken up
without concomitant internalization of the protein part, has
been proposed (8, 16, 17). The scavenger receptor class B type
I (SR-BI), exclusively present in liver and non-placental steroi-
dogenic tissues, is involved in this process (18–20). In endo-
crine tissues the SR-BI expression is regulated by trophic hor-
mones (21). Additionally, cellular cholesterol levels may
modulate SR-BI expression (22, 23). Investigations in HL-defi-
cient (knock-out) mice suggest a link between HL and SR-BI
expression (22). In female HL knock-out mice, SR-BI expres-
sion in adrenal gland was strongly enhanced. The induction of
SR-BI was suggested to result from a lowering of intracellular
cholesterol stores because of HL deficiency. An alternative
mechanism may be that SR-BI expression is stimulated com-
pensatory to changes in plasma lipoprotein metabolism be-
cause of the long-term HL deficiency. Remarkably, despite the
greatly enhanced SR-BI levels (3.5-fold), adrenal cholesterol
(ester) stores were largely depleted suggesting that the in-
crease in SR-BI did not result in adequate cholesterol supply to
support steroidogenesis. This may indicate that HL activity is
required for the optimal activation of selective HDL-cholesteryl
ester uptake.
In the present investigation we studied the impact of acute in
vivo inhibition of HL activity on adrenal SR-BI expression. In
addition, we measured the consequences for HDL-cholesteryl
ester uptake under these conditions.
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Animals—Male Wistar rats (200–300 g) were kept under controlled
conditions of humidity, light, and temperature with free access to tap
water and chow diet. The animals were fasted overnight before use.
ACTH treatment consisted of daily subcutaneous administration of 0.2
mg of Synacthen (a synthetic ACTH analogue, Ciba) per kg body weight
for 6 days. Control rats were injected daily with saline for the same
period.
In Vivo Inhibition of Hepatic Lipase Activity—The IgG fraction of
goat anti-rat HL and non-immune goat serum was isolated by protein G
affinity chromatography. The IgGs were dialyzed against 5 mM
(NH4)HCO3 and lyophilized. The obtained pellets were resuspended in
0.15 M NaCl to a concentration of 30 mg of protein/ml. The antibody
preparation was tested for its ability to inhibit HL activity of heparin-
containing rat liver perfusate. To inhibit adrenal lipase activity, the
rats were treated with an amount of antibodies that inhibited the
enzyme activity equivalent to all heparin-releasable HL activity in rats
of the same weight. Control animals were injected with the same
amount of control IgG. Four, eight, or twenty-four hours after antibody
injection, adrenals were homogenized in 10 volumes of ice-cold phos-
phate-buffered saline (pH 7.4) containing 10 IU/ml heparin and 1 mM
benzamidine. After centrifugation (10,000 3 g, 2 min, 4 °C), the post-
nuclear fraction was assayed for hepatic lipase activity as described
elsewhere (24). Enzyme activity was determined as triacylglycerol hy-
drolase and expressed as milliunits (nmol of free fatty acids released per
min).
Northern Blot and Immunoblot Analysis of SR-BI—Total tissue RNA
was isolated from adrenal glands as described (25). Adrenal RNA (7.5
mg/lane) was electrophoresed on a formaldehyde-agarose gel and trans-
ferred to a nylon membrane (Highbond-N1, Amersham). The SR-BI
cDNA probe for in situ hybridization was prepared by reverse tran-
scriptase-PCR using 1 mg of adrenal RNA. The reverse transcriptase-
PCR was performed as described previously (26), using the primers
SR-BI(1)-(59-CGG AAT TCA GGG GTG TTT GAA GGC-39) and SR-
BI(2)-(59-CGG GAT CCT GAA TGG CCT CCT TAT CC-39) according to
the human cDNA sequence (27). This primer combination yields a PCR
product of 550 base pairs, which is ;98% homologous with that of the
rat (data not shown). The RT-PCR product (550 base pairs) was ex-
tracted from agarose gel and resuspended in sterile water. A glyceral-
dehyde-3-phosphate dehydrogenase probe (570 base pairs) was also
prepared by reverse transcriptase-PCR from rat heart RNA and used as
reference. Both probes were labeled using 1 mCi of [32P]ATP. Mem-
branes were hybridized following standard methods (28). Radioactive
bands were analyzed using a GS363 Molecular Imager System from
Bio-Rad. Values of the SR-BI mRNA were normalized for glyceralde-
hyde-3-phosphate dehydrogenase contents in the same samples. Crude
membranes of adrenal glands were isolated as described elsewhere (29).
Twenty mg of membrane protein were separated by 10% SDS-polyacryl-
amide gel electrophoresis under reducing conditions (30) and trans-
ferred to a nitrocellulose membrane (Schleicher & Schuell). The mem-
branes were incubated for 2 h at room temperature with a rabbit
polyclonal anti-rat SR-BI antibody followed by incubation for 1 h with
alkaline phosphatase-conjugated goat anti-rabbit IgGs as secondary
antibody. SR-BI protein bands were detected and scanned using a
Hewlett Packard ScanJet 4C and quantified.
HDL Isolation and Labeling—Human HDL was isolated from blood
of healthy volunteers at a density between 1.063 and 1.21 g/ml by
sequential ultracentrifugation using standard techniques (31). HDL
was passed over a Sepharose-heparin column to remove apoE-contain-
ing lipoproteins (32). After dialysis against 0.15 M NaCl, containing 1
mM EDTA, pH 7.4, the lipoprotein was labeled in its lipid moiety with
[1a,2a-3H]cholesteryl oleyl ether (Amersham Pharmacia Biotech) as
described previously for LDL (33). The labeled HDL was reisolated by
gradient ultracentrifugation (33) and dialyzed against 0.15 M NaCl.
Before use the preparation was filtered through a 0.45-mm Millipore
filter. Rat HDL was isolated from blood of control animals injected with
polyclonal anti-HL antibody and sacrificed 1 h later. During this period
HL activity in the liver is inhibited 90–98%. The HDL fraction was
isolated and handled as described above for human HDL, except that
the lipoprotein fraction was collected at density between 1.050 and 1.21
g/ml. The labeling of rat HDL occurred in the presence of human
lipoprotein-deficient serum as a source of cholesteryl ester transfer
protein (33).
HDL-[3H]CEth Uptake in Vivo—To study adrenal HDL[3H]CEth up-
take in vivo, two different procedures were used. In the first procedure
rats were intravenously injected with 0.1 ml of concentrated anti-HL or
non-immune IgG preparation. Four hours later 0.2 ml of human HDL-
[3H]cholesteryl ether solution, corresponding to 124 nmol of total cho-
lesterol and 1 3 106 dpm, was injected intravenously. Animals were
sacrificed 4 or 24 h after the injection of labeled HDL. In the second
procedure, animals were intravenously injected with 0.1 ml of concen-
trated anti-HL or non-immune IgG preparation. Two hours later 0.2 ml
of rat HDL[3H]CEth corresponding to 100 nmol of total cholesterol and
1 3 106 dpm was intravenously injected. Two hours after the injection
of the labeled HDL, 0.1 ml of concentrated anti-HL or control IgGs were
administrated again. Animals were sacrificed 4 h after the labeled
lipoprotein injection. The adrenals were excised, cleaned from adherent
fat tissue, and weighed. Tissue samples were dissolved in Soluene-350
(Packard Instrument) for 4 h at 55 °C and analyzed for radioactivity.
The radioactivity in the adrenals was corrected for contamination of
plasma radioactivity and used 9.9% (v/w) plasma per organ (34). In the
experiments with rat HDL the radioactivity in the adrenals was also
corrected for the increase in HDL-cholesteryl esters between 2 and 4 h
after the antibody injection (12.3%) (12).
RESULTS
HL activity was lowered in vivo by administration of HL
activity inhibiting antibodies. Four hours after anti-HL admin-
istration to control (not ACTH-treated) rats, the adrenal lipase
activity was inhibited by 68% (Table I). The adrenal HL activ-
ity remained inhibited for at least 4 h. After 8 h the adrenal HL
activity was still 40% lower than in controls (non-immune)
(2.21 6 0.36 versus 3.68 6 0.46 milliunits/organ). After 24 h,
the adrenal lipase activity had increased to 2- to 3-fold over the
basal activity. Four hours after the injection of anti-HL anti-
body into control (not ACTH-treated) animals the adrenal
SR-BI mRNA content was greatly increased (5.2-fold) (Table I).
SR-BI mass increased during the same period by 66%. Twenty-
four h after the injection of anti-HL, when HL activity had
increased above the basal activity, SR-BI mRNA was about
18% below control values (n.s.). SR-BI mass, however, re-
mained increased at the level already reached 4 h after inhibi-
tion of HL activity.
In the following experiments we studied the consequences of
the changes in HL activity and SR-BI expression for the adre-
nal uptake of HDL-cholesteryl ester. To this end, the rats were
injected with HDL labeled with a non-degradable cholesteryl
ester analogue, [3H]cholesteryl ether (HDL-[3H]CEth). The ac-
cumulation of radioactivity represents the uptake of HDL-
[3H]cholesteryl ether (HDL-[3H]CEth) as an estimation of
HDL-cholesteryl ester. In the first 4 h after administration of
labeled human HDL, 72.0 6 2.4% of the injected HDL-
[3H]CEth was cleared from the plasma compartment in control
rats, compared with 66.0 6 2.7% in antibody-treated rats (n.s).
Most of this label is removed by the liver (not shown). The
adrenals took up 0.58 6 0.11% of the total injected dose during
this time period (Fig. 1). In rats treated with anti-HL, the
TABLE I
In vivo effect of anti-HL antibody administration on adrenal HL
activity and SR-BI expression in control rats
Animals were injected with goat non-immune IgG (control IgG) or
with a goat polyclonal anti-hepatic lipase antibody (anti-HL) and sac-
rificed after 4 h or 24 h. Adrenal glands were removed, homogenized,
and assayed for HL activity. HL activity was assayed as triacylglycerol
hydrolase and expressed as milliunits (nanomoles of free fatty acids
released per min) per 2 adrenals. SR-BI mRNA and mass were deter-
mined as described under “Experimental Procedures.” Values are
mean 6 S.D. (n 5 7) except for HL activity at 24 h (n 5 3) and for SR-BI
expression (n 5 3). All values are statistically significant if compared
with control IgG, except when NS is indicated using one way analysis of
variance with the Student-Newman-Keuls test.
HL activity SR-BI mRNA SR-BI mass
(total milliunits/organ) (A.U./organ) (A.U./organ)
Control IgG (4 h) 3.68 6 0.46 2.9 6 0.7 7.7 6 1.8
Anti-HL (4 h) 1.18 6 0.48a 15.1 6 4.2a 12.8 6 0.4a
Anti-HL (24 h) 8.38 6 1.08a 2.4 6 0.6NS 13.7 6 3.5a
a p , 0.0001.
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adrenal uptake of HDL-[3H]CEth was 41% higher than in the
controls. This effect on adrenal HDL-[3H]CEth uptake was also
present when the rats were studied 24 h after HDL-[3H]CEth
injection, although it tended to be smaller (Fig. 1). Additional
experiments were carried out using HDL isolated from rats in
which HL activity had been functionally inactivated by anti-HL
antibody for 1 h. In the first 4 h after the administration of rat
HDL-[3H]CEth about 50% (controls, 53.0 6 5.2%; anti-HL-
treated rats, 47.6 6 3.0%, n.s.) of the label was cleared from the
plasma compartment. During this period control adrenals took
up 0.47 6 0.12% of the injected dose per organ. In rats treated
with anti-HL, the adrenal uptake was increased by 68% (Fig. 1)
(0.47 6 0.12, n 5 4 versus 0.79 6 0.18, n 5 5, p , 0.02). From
these experiments, we concluded that SR-BI rather than HL
activity corresponds with the uptake of HDL-cholesteryl ester
in the adrenal gland. On the other hand, SR-BI expression may
be modulated by changes in HL activity.
Next we studied whether HL activity may affect HDL-cho-
lesteryl ester uptake when the adrenal gland is stimulated by
ACTH treatment and HL activity is greatly enhanced. Rats
were treated with ACTH for 6 days, leading to about a 2-fold
increase in HL activity (107 6 13 versus 213 6 50 milliunits/g
wet weight). Because the adrenal weight increased during
ACTH treatment (35 6 5 versus 174 6 61 mg/2 adrenals), the
total lipase activity in the adrenals increased even more (9.2-
fold) (Fig. 2). Under these conditions SR-BI expression is also
greatly enhanced (Fig. 2). Total SR-BI mRNA in stimulated
adrenals was 30-fold higher than in the control (2.9 6 0.7
versus 86.8 6 41.1 A.U./2 adrenals). SR-BI mass was less
increased (4.9 6 0.6 versus 19.5 6 14.8 A.U./mg of protein) (Fig.
2), but total SR-BI mass in the adrenals was 8.1-fold higher
than in the controls (7.7 6 1.8 versus 63.2 6 46.7 A.U./2
adrenals). Under these conditions, the stimulated adrenals
took up 7.2% of the injected dose of (HDL-[3H]CEth) in 4 h,
which is about 12 times more than in the unstimulated adre-
nals (Fig. 2). Inhibition of HL activity under these conditions
had no effect on SR-BI expression either in total mRNA (86.8 6
41.1 versus 67.1 6 9.9 A.U./2 adrenals) or in total SR-BI mass
(63.2 6 46.7 versus 60.9 6 33.6 A.U./2 adrenals). In addition,
inhibition of HL activity did not influence [3H]CEth uptake
(7.24 6 1.58 versus 6.67 6 1.40% of injected dose/2 adrenals) in
ACTH-treated rats for 4 h.
DISCUSSION
Several mechanisms have been proposed for the (selective)
uptake of HDL-cholesteryl ester in the adrenal gland. Both
L-type lipase, the adrenal form of HL, and SR-BI may play a
role in adrenal cholesterol homeostasis. In vitro, several stud-
ies on the effect of HL on HDL-cholesterol (ester) uptake in
cultured cells have been reported, but no in vivo data are
available. HL and SR-BI expression may be coordinately reg-
ulated. Gene-targeted inactivation of HL in mice was found to
be associated with increased expression of SR-BI. Despite the
increase in SR-BI expression, adrenal cholesteryl ester stores
were partly depleted (22). This suggested that the induction of
SR-BI could not fully compensate for the loss of HL activity in
cholesterol homeostasis. The effect of the increased SR-BI on
HDL-cholesteryl ester uptake was not evaluated. In the pres-
FIG. 2. Effect of ACTH treatment on rat adrenal HDL-[3H]CEth
uptake and SR-BI expression. Control and ACTH animals were
treated with control IgG and sacrificed 4 h later. Both adrenals were
removed subsequently and frozen. HL activity and SR-BI mRNA and
mass were analyzed by enzymatic assay, Northern blot, and immuno-
blot, respectively, as described under “Experimental Procedures.” The
figure shows a representative experiment of Northern blot and immu-
noblot. HDL-[3H]CEth was injected 4 h after the IgG and the animals
were sacrificed 4 h later in order to measure the uptake of radioactivity
in the adrenal glands. Values are mean 6 S.D. (n 5 4) except for HL
activity (n 5 7).
FIG. 1. Effect of HL activity inhibi-
tion on HDL-[3H]CEth uptake by ad-
renal glands of control rats. The rats
were injected with control IgGs or with a
polyclonal anti-rat HL antibody prepara-
tion. Labeled rat (r) or human (h) HDL
was intravenously injected 2 or 4 h later,
respectively, as described under “Experi-
mental Procedures.” The animals were
sacrificed 4 h or 24 h later. HDL-[3H]CEth
uptake by adrenal glands was expressed
as percentage of the injected dose per or-
gan. Values are mean 6 S.D. (n 5 4). The
effect of anti-HL was tested using one-
way analysis of variance with the Stu-
dent-Newman-Keuls test.
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ent study, we determined the effect of an acute inhibition of
adrenal HL activity on SR-BI expression and on HDL-cho-
lesteryl ether uptake in vivo. Administration of anti-HL to rats
leads to a rapid inactivation of HL activity in adrenals and
liver. The adrenal HL turnover is relatively slow. Once adrenal
lipase activity is inhibited it remains lowered during at least
8 h, while the HL activity in the liver is restored to control
values in 4 h. Twenty-four hours after the injection of antibody
the adrenal lipase activity is increased above the control val-
ues. Acute inhibition of HL in the adrenal gland led to a greatly
increased expression of SR-BI within 4 h, which was accompa-
nied by a significant increase in HDL-[3H]CEth uptake. Twen-
ty-four hours after antibody administration, SR-BI expression
had returned to control values. The actual rate of adrenal
uptake of HDL-cholesteryl esters at this time point cannot be
determined as the major part of HDL-[3H]CEth uptake is by
the liver (35) and takes place within the first 4 h after injection.
Between 4 and 24 h after HDL-[3H]CEth administration the
increase in uptake of label in the adrenal gland was much
smaller in the antibody-treated animals than in the controls. In
this time period SR-BI mRNA decreased to control values in
the antibody-treated animals. This may partly explain the
lower rate of uptake of HDL-[3H]CEth in the adrenals. We also
used rat HDL isolated from animals in which HL activity had
been functionally inactivated for 1 h. Therefore, this HDL had
hardly been processed by HL in vivo prior to intravenous in-
jection and is enriched in phospholipids and cholesterol (12).
Uptake of [3H]CEth from these “unprocessed” homologous rat
HDL was similar to that from human HDL. Our data are
compatible with a model in which adrenal HL activity is a
determinant of SR-BI expression and SR-BI is the most impor-
tant determinant of HDL-[3H]CEth uptake. The latter is fur-
ther supported by findings in ACTH pretreated rats. ACTH
pretreatment led to a considerable increase in SR-BI expres-
sion, adrenal HL activity, and HDL-[3H]CEth uptake. The in-
crease in SR-BI mass was in line with the increased HDL-
[3H]CEth uptake. In stimulated rats the inhibition of HL did
not affect either SR-BI expression or HDL-[3H]CEth uptake.
This clearly rules out adrenal HL activity as a major determi-
nant of HDL-cholesteryl ester uptake under these conditions.
The mechanism of the interaction between adrenal HL activity
and SR-BI expression in the control rats can only be speculated
about. HL is an enzyme with high phospholipase activity. Its
preferred substrates are HDL-phospholipids. HL has been
shown to be able to modulate HDL-unesterified cholesterol
fluxes between HDL and cells and specifically to diminish the
efflux of cholesterol from cells to HDL (36, 37). SR-BI expres-
sion is likely to be regulated by the cellular cholesterol content
(22). Therefore, it could be that in vivo inhibition of HL leads to
an increased efflux (or diminished influx) of non-esterified cho-
lesterol in the adrenal gland which in turn gives rise to induc-
tion of SR-BI expression. Subsequently, SR-BI may stimulate
HDL-cholesteryl ester uptake. In this model the primary role of
HL would be in the modulation of fluxes of unesterified HDL-
cholesterol and that of SR-BI in the mediation of HDL-cho-
lesteryl ester uptake. Taken together, HL and SR-BI may be
part of mechanisms ensuring an optimal cholesterol supply for
steroid hormone synthesis under a variety of conditions.
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